Scleroderma



Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)


Conditions:   Systemic Sclerosis;   Scleroderma
Interventions:   Drug: Tofacitinib;   Drug: Placebo Oral Tablet
Sponsors:   University of Michigan;   Pfizer
Recruiting



MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients


Condition:   Scleroderma
Intervention:   Other: unenhanced MR sequences
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Centrale Supelec School (Center for Visual Computing)
Not yet recruiting


The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy


Condition:   Scleroderma
Interventions:   Other: Physalis angulata ethanol extract;   Other: Placebo
Sponsors:   Indonesia University;   Netherlands: Ministry of Health, Welfare and Sports
Completed


Scleroderma Patient-centered Intervention Network (SPIN) Hand Program Feasibility Study


Conditions:   Scleroderma;   Systemic Sclerosis
Intervention:   Other: SPIN-HAND program
Sponsors:   Lady Davis Institute;   Hôpital Cochin
Recruiting


Riociguat in Scleroderma Associated Digital Ulcers


Conditions:   Scleroderma;   Digital Ulcers
Interventions:   Drug: Riociguat;   Drug: Placebo
Sponsors:   Dinesh Khanna, MD, MS;   Bayer
Recruiting


Duke Scleroderma Clinic Patient Registry


Conditions:   Scleroderma;   Systemic Sclerosis
Intervention:   Other: Registry
Sponsor:   Duke University
Recruiting


Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma


Conditions:   Scleroderma;   Ssc
Intervention:   Other: Occupational therapy treatment
Sponsors:   University of Michigan;   University of Alabama at Birmingham
Recruiting


Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers


Condition:   Digital Ulcer of Scleroderma
Interventions:   Drug: Diltiazem Gel 2%;   Drug: Nitroglycerin Ointment 2%;   Drug: Vaseline
Sponsors:   Mohammad Ali Nazarinia;   Shiraz University of Medical Sciences
Completed


Hands on - a Hand Care Guide in Systemic Sclerosis


Condition:   Scleroderma
Intervention:   Other: Handbook
Sponsor:   University of Campinas, Brazil
Active, not recruiting


A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis


Condition:   Scleroderma, Systemic
Interventions:   Drug: Nintedanib;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Recruiting


Taking Charge of Systemic Sclerosis


Condition:   Scleroderma
Interventions:   Other: Internet-based self-management program;   Other: Scleroderma book
Sponsors:   University of Michigan;   University of New Mexico;   Medical University of South Carolina;   Patient-Centered Outcomes Research Institute
Active, not recruiting


Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma


Conditions:   Scleroderma;   Interstitial Lung Disease
Intervention:   Drug: dabigatran etexilate
Sponsors:   Medical University of South Carolina;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting


Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma


Condition:   Scleroderma
Interventions:   Drug: atorvastatin;   Drug: Placebo
Sponsors:   Robyn T. Domsic, MD, MPH;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting


Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial


Condition:   Systemic Scleroderma
Interventions:   Drug: C-82 Topical Gel, 1%;   Drug: C-82 Topical Gel, Placebo
Sponsor:   Prism Pharma Co., Ltd.
Completed


Calcinosis in a Single-Center Scleroderma Population


Conditions:   Scleroderma;   Calcinosis
Intervention:  
Sponsor:   Rutgers, The State University of New Jersey
Recruiting


Scleroderma ARFI Imaging of the Skin


Condition:   Scleroderma
Intervention:   Device: ARFI-SVI Ultrasound
Sponsor:   University of Michigan
Completed


Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma


Condition:   Localized Scleroderma
Interventions:   Device: Fractional carbon dioxide laser;   Device: Ultraviolet A1 phototherapy (UVA1)
Sponsor:   Cairo University
Unknown status


IVIG Treatment in Systemic Sclerosis


Conditions:   Systemic Sclerosis;   Diffuse Scleroderma
Intervention:   Biological: Privigen
Sponsors:   Georgetown University;   CSL Behring
Active, not recruiting


Scleroderma Registry & Repository at the Hospital for Special Surgery


Condition:   Scleroderma
Intervention:  
Sponsor:   Hospital for Special Surgery, New York
Recruiting


Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis


Condition:   Scleroderma
Intervention:   Drug: Lactobacillus
Sponsor:   University of Michigan
Withdrawn


Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial


Condition:   Scleroderma
Interventions:   Procedure: Cytoxan rATG/Fludarabine/HSCT;   Procedure: Cytoxan rATG/HSCT
Sponsor:   Northwestern University
Recruiting


Scleroderma Treatment With Autologous Transplant (STAT) Study


Condition:   Systemic Scleroderma
Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting


Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis


Conditions:   Systemic Scleroderma;   Severe Systemic Sclerosis
Interventions:   Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
Sponsors:   Fred Hutchinson Cancer Research Center;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting


High Dose Cyclophosphamide for Treatment of Scleroderma


Condition:   Scleroderma
Intervention:   Drug: IV Cyclophosphamide
Sponsor:   Johns Hopkins University
Completed

Refine Your Search Advanced Search